Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
NCT02946944 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2016-11-01
Summary
Pilot randomized study of the sidlenafil efficacy in combination with oral anticoagulants in the treatment of patients with intermediate-high risk of pulmonary embolism
Conditions
- Pulmonary Embolism
- Intermediate-high Risk
- Combination of Oral Anticoagulation Therapy and Sildenafil
Interventions
- DRUG
-
Sildenafil/apixaban
After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
- DRUG
-
apixaban
After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Sponsors & Collaborators
-
Meshalkin Research Institute of Pathology of Circulation
lead NETWORK
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-31
- Primary Completion
- 2020-10-31
- Completion
- 2020-10-31
Countries
- Russia
Study Locations
More Related Trials
-
Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication
NCT02930811 ·Status: WITHDRAWN ·Phase: PHASE3
-
Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery
NCT01481350 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Oral Sildenafil on Mortality in Adults With PAH
NCT02060487 ·Status: TERMINATED ·Phase: PHASE4
-
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
NCT01897740 ·Status: NO_LONGER_AVAILABLE
-
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
NCT02387450 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
NCT00946114 ·Status: COMPLETED
-
Sildenafil in US Heart Failure Patients (SilHF-US)
NCT03460470 ·Status: UNKNOWN ·Phase: PHASE3
-
Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication
NCT02832570 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
NCT01290484 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00323297 ·Status: COMPLETED ·Phase: PHASE4
-
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
NCT01812434 ·Status: WITHDRAWN ·Phase: NA
-
Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
NCT03686813 ·Status: COMPLETED ·Phase: PHASE2
-
Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
NCT00334490 ·Status: COMPLETED ·Phase: PHASE2
-
Sildenafil for Chronic Obstructive Pulmonary Disease
NCT00104637 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation
NCT00964782 ·Status: COMPLETED ·Phase: PHASE4
-
Sildenafil in Heart Failure With Reactive Pulmonary Hypertension
NCT02304705 ·Status: TERMINATED ·Phase: PHASE4
-
Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
NCT00352482 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
NCT01365585 ·Status: COMPLETED
-
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
NCT00517933 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms
NCT02345980 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
NCT00878943 ·Status: NO_LONGER_AVAILABLE
-
Sildenafil in Single Ventricle Patients
NCT01169519 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label Access Study For Subjects Who Completed A1481156
NCT01582438 ·Status: NO_LONGER_AVAILABLE
-
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
NCT00159887 ·Status: COMPLETED ·Phase: PHASE3
-
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
NCT00359736 ·Status: COMPLETED ·Phase: PHASE2